Renal Transport of Uric Acid: Evolving Concepts and Uncertainties

Advances in Chronic Kidney Disease

Volumn 19, Issue 6, 2012, Pages 358-371

  Bobulescu, Ion Alexandru ^a   Moe, Orson W ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

GLUT9; Hyperuricemia; Hypouricemia; URAT1; Urate

Indexed keywords

ANTIOXIDANT; BENZBROMARONE; BREAST CANCER RESISTANCE PROTEIN; CARRIER PROTEIN; CREATININE; FUROSEMIDE; INTERLEUKIN 1BETA; LESINURAD; LOSARTAN; ORGANIC ANION TRANSPORTER 4; PROBENECID; PYRAZINAMIDE; URATE; URATE OXIDASE; URIC ACID;

BLOOD PRESSURE; CREATININE CLEARANCE; DISEASE ASSOCIATION; GENE EXPRESSION; GENETIC ASSOCIATION; GOUT; HUMAN; HYPERURICEMIA; KIDNEY TUBULE ABSORPTION; LOSS OF FUNCTION MUTATION; MOLECULAR MECHANICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PURINE METABOLISM; REVIEW; UNCERTAINTY; URINARY EXCRETION;

BIOLOGICAL TRANSPORT; GLUCOSE TRANSPORT PROTEINS, FACILITATIVE; GOUT; HUMANS; HYPERURICEMIA; KIDNEY; KIDNEY TUBULES, PROXIMAL; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS; UNCERTAINTY; URIC ACID;

EID: 84867866650     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2012.07.009     Document Type: Review

References (106)

1. Nuki G., Simkin P.A. A concise history of gout and hyperuricemia and their treatment. Arthritis Res Ther 2006, 8(suppl 1):S1.
2. Richet G. The chemistry of urinary stones around 1800: a first in clinical chemistry. Kidney Int 1995, 48:876-886.
3. Thomson T. Chemistry of Animal Bodies. 1858: Edinburgh, UK: 31. Digitized version available at http://books.google.com.
4. Brondino C.D., Romao M.J., Moura I., Moura J.J. Molybdenum and tungsten enzymes: the xanthine oxidase family. Curr Opin Chem Biol 2006, 10:109-114.
5. Schlesinger N. New agents for the treatment of gout and hyperuricemia: febuxostat, puricase, and beyond. Curr Rheumatol Rep 2010, 12:130-134.
6. Maesaka J.K., Fishbane S. Regulation of renal urate excretion: a critical review. Am J Kidney Dis 1998, 32:917-933.
7. Sorensen L.B., Levinson D.J. Origin and extrarenal elimination of uric acid in man. Nephron 1975, 14:7-20.
8. Sakhaee K., Adams-Huet B., Moe O.W., Pak C.Y. Pathophysiologic basis for normouricosuric uric acid nephrolithiasis. Kidney Int 2002, 62:971-979.
9. Oda M., Satta Y., Takenaka O., Takahata N. Loss of urate oxidase activity in hominoids and its evolutionary implications. Mol Biol Evol 2002, 19:640-653.
10. Wu X., Wakamiya M., Vaishnav S., et al. Hyperuricemia and urate nephropathy in urate oxidase-deficient mice. Proc Natl Acad Sci U S A 1994, 91:742-746.
11. Watanabe S., Kang D.H., Feng L., et al. Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 2002, 40:355-360.
12. Giebisch G, Kennedy T. National Academy of Sciences Biographical Memoir: Robert W. Berliner, 1915-2002. Available at: Accessed August 1, 2012. http://www.nasonline.org/publications/biographical-memoirs/memoir-pdfs/berliner-robert-w.pdf.
13. Gutman A.B. Renal excretion of uric acid in normal and gouty man. Arthritis Rheum 1965, 8:665-670.
14. Shoemaker V.H., Nagy K.A. Osmoregulation in amphibians and reptiles. Annu Rev Physiol 1977, 39:449-471.
15. Braun E.J. Integration of organ systems in avian osmoregulation. J Exp Zool 1999, 283:702-707.
16. Ames B.N., Cathcart R., Schwiers E., Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A 1981, 78:6858-6862.
17. Frei B., England L., Ames B.N. Ascorbate is an outstanding antioxidant in human blood plasma. Proc Natl Acad Sci U S A 1989, 86:6377-6381.
18. Kuzkaya N., Weissmann N., Harrison D.G., Dikalov S. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol 2005, 70:343-354.
19. Gagliardi A.C., Miname M.H., Santos R.D. Uric acid: a marker of increased cardiovascular risk. Atherosclerosis 2009, 202:11-17.
20. Hayden M.R., Tyagi S.C. Uric acid: a new look at an old risk marker for cardiovascular disease, metabolic syndrome, and type 2 diabetes mellitus: the urate redox shuttle. Nutr Metab (Lond) 2004, 1:10.
21. Sautin Y.Y., Johnson R.J. Uric acid: the oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids 2008, 27:608-619.
22. Hershfield M.S., Roberts L.J., Ganson N.J., et al. Treating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivo. Proc Natl Acad Sci U S A 2010, 107:14351-14356.
23. Johnson R.J., Segal M.S., Srinivas T., et al. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link?. J Am Soc Nephrol 2005, 16:1909-1919.
24. Feig D.I., Soletsky B., Johnson R.J. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 2008, 300:924-932.
25. Shi Y., Evans J.E., Rock K.L. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003, 425:516-521.
26. Martinon F., Petrilli V., Mayor A., Tardivel A., Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006, 440:237-241.
27. Passwell J.H., Modan M., Brish M., Orda S., Boichis H. Fractional excretion of uric acid in infancy and childhood. Index of tubular maturation. Arch Dis Child 1974, 49:878-882.
28. Stapleton F.B., Linshaw M.A., Hassanein K., Gruskin A.B. Uric acid excretion in normal children. J Pediatr 1978, 92:911-914.
29. Stiburkova B., Bleyer A.J. Changes in serum urate and urate excretion with age. Adv Chronic Kidney Dis 2012, 19.
30. Baum M., Quigley R., Satlin L. Maturational changes in renal tubular transport. Curr Opin Nephrol Hypertens 2003, 12:521-526.
31. Dan T., Tanaka H., Koga H. Mechanism of uricosuric action of AA-193 in DBA/2N mice. J Pharmacol Exp Ther 1990, 253:437-443.
32. Preitner F., Bonny O., Laverriere A., et al. Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc Natl Acad Sci U S A 2009, 106:15501-15506.
33. Diamond H.S., Paolino J.S. Evidence for a postsecretory reabsorptive site for uric acid in man. J Clin Invest 1973, 52:1491-1499.
34. Gutman A.B., Yu T.F., Berger L. Tubular secretion of urate in man. J Clin Invest 1959, 38:1778-1781.
35. Guggino S.E., Aronson P.S. Paradoxical effects of pyrazinoate and nicotinate on urate transport in dog renal microvillus membranes. J Clin Invest 1985, 76:543-547.
36. Enomoto A., Kimura H., Chairoungdua A., et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002, 417:447-452.
37. So A., Thorens B. Uric acid transport and disease. J Clin Invest 2010, 120:1791-1799.
38. Anzai N., Endou H. Urate transporters: an evolving field. Semin Nephrol 2011, 31:400-409.
39. Lipkowitz M.S. Regulation of uric acid excretion by the kidney. Curr Rheumatol Rep 2012, 14:179-188.
40. Tanaka M., Itoh K., Matsushita K., et al. Two male siblings with hereditary renal hypouricemia and exercise-induced ARF. Am J Kidney Dis 2003, 42:1287-1292.
41. Wakida N., Tuyen D.G., Adachi M., et al. Mutations in human urate transporter 1 gene in presecretory reabsorption defect type of familial renal hypouricemia. J Clin Endocrinol Metab 2005, 90:2169-2174.
42. Ichida K., Hosoyamada M., Kamatani N., et al. Age and origin of the G774A mutation in SLC22A12 causing renal hypouricemia in Japanese. Clin Genet 2008, 74:243-251.
43. Kolz M., Johnson T., Sanna S., et al. Meta-analysis of 28,141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009, 5:e1000504.
44. Tin A., Woodward O.M., Kao W.H., et al. Genome-wide association study for serum urate concentrations and gout among African Americans identifies genomic risk loci and a novel URAT1 loss-of-function allele. Hum Mol Genet 2011, 20:4056-4068.
45. Kenny E.E., Kim M., Gusev A., et al. Increased power of mixed models facilitates association mapping of 10 loci for metabolic traits in an isolated population. Hum Mol Genet 2011, 20:827-839.
46. Mori K., Ogawa Y., Ebihara K., et al. Kidney-specific expression of a novel mouse organic cation transporter-like protein. FEBS Lett 1997, 417:371-374.
47. Hosoyamada M., Ichida K., Enomoto A., Hosoya T., Endou H. Function and localization of urate transporter 1 in mouse kidney. J Am Soc Nephrol 2004, 15:261-268.
48. Eraly S.A., Vallon V., Rieg T., et al. Multiple organic anion transporters contribute to net renal excretion of uric acid. Physiol Genomics 2008, 33:180-192.
49. Phay J.E., Hussain H.B., Moley J.F. Cloning and expression analysis of a novel member of the facilitative glucose transporter family, SLC2A9 (GLUT9). Genomics 2000, 66:217-220.
50. Augustin R., Carayannopoulos M.O., Dowd L.O., et al. Identification and characterization of human glucose transporter-like protein-9 (GLUT9): alternative splicing alters trafficking. J Biol Chem 2004, 279:16229-16236.
51. Li S., Sanna S., Maschio A., et al. The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts. PLoS Genet 2007, 3:e194.
52. Dehghan A., Kottgen A., Yang Q., et al. Association of three genetic loci with uric acid concentration and risk of gout: a genome-wide association study. Lancet 2008, 372:1953-1961.
53. Doring A., Gieger C., Mehta D., et al. SLC2A9 influences uric acid concentrations with pronounced sex-specific effects. Nat Genet 2008, 40:430-436.
54. Vitart V., Rudan I., Hayward C., et al. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008, 40:437-442.
55. Wallace C., Newhouse S.J., Braund P., et al. Genome-wide association study identifies genes for biomarkers of cardiovascular disease: serum urate and dyslipidemia. Am J Hum Genet 2008, 82:139-149.
56. Anzai N., Ichida K., Jutabha P., et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008, 283:26834-26838.
57. Matsuo H., Chiba T., Nagamori S., et al. Mutations in glucose transporter 9 gene SLC2A9 cause renal hypouricemia. Am J Hum Genet 2008, 83:744-751.
58. Kawamura Y., Matsuo H., Chiba T., et al. Pathogenic GLUT9 mutations causing renal hypouricemia type 2 (RHUC2). Nucleosides Nucleotides Nucleic Acids 2011, 30:1105-1111.
59. Dinour D., Gray N.K., Campbell S., et al. Homozygous SLC2A9 mutations cause severe renal hypouricemia. J Am Soc Nephrol 2010, 21:64-72.
60. Dinour D., Gray N.K., Ganon L., et al. Two novel homozygous SLC2A9 mutations cause renal hypouricemia type 2. Nephrol Dial Transplant 2012, 27:1035-1041.
61. Bibert S., Hess S.K., Firsov D., et al. Mouse GLUT9: evidences for a urate uniporter. Am J Physiol Renal Physiol 2009, 297:F612-F619.
62. Keembiyehetty C., Augustin R., Carayannopoulos M.O., et al. Mouse glucose transporter 9 splice variants are expressed in adult liver and kidney and are up-regulated in diabetes. Mol Endocrinol 2006, 20:686-697.
63. Shikhman A.R., Brinson D.C., Valbracht J., Lotz M.K. Cytokine regulation of facilitated glucose transport in human articular chondrocytes. J Immunol 2001, 167:7001-7008.
64. Bahn A., Hagos Y., Reuter S., et al. Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13). J Biol Chem 2008, 283:16332-16341.
65. Gopal E., Umapathy N.S., Martin P.M., et al. Cloning and functional characterization of human SMCT2 (SLC5A12) and expression pattern of the transporter in kidney. Biochim Biophys Acta 2007, 1768:2690-2697.
66. Thangaraju M., Ananth S., Martin P.M., et al. c/ebpdelta Null mouse as a model for the double knock-out of slc5a8 and slc5a12 in kidney. J Biol Chem 2006, 281:26769-26773.
67. Frank H., Groger N., Diener M., et al. Lactaturia and loss of sodium-dependent lactate uptake in the colon of SLC5A8-deficient mice. J Biol Chem 2008, 283:24729-24737.
68. Eraly S.A., Hamilton B.A., Nigam S.K. Organic anion and cation transporters occur in pairs of similar and similarly expressed genes. Biochem Biophys Res Commun 2003, 300:333-342.
69. Cha S.H., Sekine T., Kusuhara H., et al. Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J Biol Chem 2000, 275:4507-4512.
70. Ekaratanawong S., Anzai N., Jutabha P., et al. Human organic anion transporter 4 is a renal apical organic anion/dicarboxylate exchanger in the proximal tubules. J Pharmacol Sci 2004, 94:297-304.
71. Hagos Y., Stein D., Ugele B., Burckhardt G., Bahn A. Human renal organic anion transporter 4 operates as an asymmetric urate transporter. J Am Soc Nephrol 2007, 18:430-439.
72. Yang Q., Kottgen A., Dehghan A., et al. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 2010, 3:523-530.
73. van der Harst P., Bakker S.J., de Boer R.A., et al. Replication of the five novel loci for uric acid concentrations and potential mediating mechanisms. Hum Mol Genet 2010, 19:387-395.
74. Ho H.T., Ko B.C., Cheung A.K., et al. Generation and characterization of sodium-dicarboxylate cotransporter-deficient mice. Kidney Int 2007, 72:63-71.
75. Leal-Pinto E., Tao W., Rappaport J., et al. Molecular cloning and functional reconstitution of a urate transporter/channel. J Biol Chem 1997, 272:617-625.
76. Lipkowitz M.S., Leal-Pinto E., Rappoport J.Z., Najfeld V., Abramson R.G. Functional reconstitution, membrane targeting, genomic structure, and chromosomal localization of a human urate transporter. J Clin Invest 2001, 107:1103-1115.
77. Hyink D.P., Rappoport J.Z., Wilson P.D., Abramson R.G. Expression of the urate transporter/channel is developmentally regulated in human kidneys. Am J Physiol Renal Physiol 2001, 281:F875-F886.
78. Werner A., Moore M.L., Mantei N., et al. Cloning and expression of cDNA for a Na/Pi cotransport system of kidney cortex. Proc Natl Acad Sci U S A 1991, 88:9608-9612.
79. Chong S.S., Kristjansson K., Zoghbi H.Y., Hughes M.R. Molecular cloning of the cDNA encoding a human renal sodium phosphate transport protein and its assignment to chromosome 6p21.3-p23. Genomics 1993, 18:355-359.
80. Ruddy D.A., Kronmal G.S., Lee V.K., et al. A 1.1-Mb transcript map of the hereditary hemochromatosis locus. Genome Res 1997, 7:441-456.
81. Biber J., Custer M., Werner A., Kaissling B., Murer H. Localization of NaPi-1, a Na/Pi cotransporter, in rabbit kidney proximal tubules. II. Localization by immunohistochemistry. Pflugers Arch 1993, 424:210-215.
82. Ishibashi K., Matsuzaki T., Takata K., Imai M. Identification of a new member of type I Na/phosphate co-transporter in the rat kidney. Nephron Physiol 2003, 94:10-18.
83. Jutabha P., Anzai N., Kitamura K., et al. Human sodium phosphate transporter 4 (hNPT4/SLC17A3) as a common renal secretory pathway for drugs and urate. J Biol Chem 2010, 285:35123-35132.
84. Biber J., Hernando N., Forster I., Murer H. Regulation of phosphate transport in proximal tubules. Pflugers Arch 2009, 458:39-52.
85. Urano W., Taniguchi A., Anzai N., et al. Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout. Ann Rheum Dis 2010, 69:1232-1234.
86. Hollis-Moffatt J.E., Phipps-Green A.J., Chapman B., et al. The renal urate transporter SLC17A1 locus: confirmation of association with gout. Arthritis Res Ther 2012, 14:R92.
87. Iharada M., Miyaji T., Fujimoto T., et al. Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J Biol Chem 2010, 285:26107-26113.
88. Doyle L.A., Yang W., Abruzzo L.V., et al. A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 1998, 95:15665-15670.
89. Woodward O.M., Kottgen A., Coresh J., et al. Identification of a urate transporter, ABCG2, with a common functional polymorphism causing gout. Proc Natl Acad Sci U S A 2009, 106:10338-10342.
90. Yamagishi K., Tanigawa T., Kitamura A., et al. The rs2231142 variant of the ABCG2 gene is associated with uric acid levels and gout among Japanese people. Rheumatology (Oxford) 2010, 49:1461-1465.
91. Phipps-Green A.J., Hollis-Moffatt J.E., Dalbeth N., et al. A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Maori, case and control sample sets. Hum Mol Genet 2010, 19:4813-4819.
92. Huls M., Brown C.D., Windass A.S., et al. The breast cancer resistance protein transporter ABCG2 is expressed in the human kidney proximal tubule apical membrane. Kidney Int 2008, 73:220-225.
93. Matsuo H., Takada T., Ichida K., et al. Common defects of ABCG2, a high-capacity urate exporter, cause gout: a function-based genetic analysis in a Japanese population. Sci Transl Med 2009, 1:5ra11.
94. Hosomi A., Nakanishi T., Fujita T., Tamai I. Extra-renal elimination of uric acid via intestinal efflux transporter BCRP/ABCG2. PloS One 2012, 7:e30456.
95. Ichida K., Matsuo H., Takada T., et al. Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun 2012, 3:764.
96. Maliepaard M., Scheffer G.L., Faneyte I.F., et al. Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res 2001, 61:3458-3464.
97. van Aubel R.A., Smeets P.H., Peters J.G., Bindels R.J., Russel F.G. The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J Am Soc Nephrol 2002, 13:595-603.
98. Lee K., Belinsky M.G., Bell D.W., Testa J.R., Kruh G.D. Isolation of MOAT-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-related transporter. Cancer Res 1998, 58:2741-2747.
99. Bakhiya A., Bahn A., Burckhardt G., Wolff N. Human organic anion transporter 3 (hOAT3) can operate as an exchanger and mediate secretory urate flux. Cell Physiol Biochem 2003, 13:249-256.
100. Ichida K., Hosoyamada M., Kimura H., et al. Urate transport via human PAH transporter hOAT1 and its gene structure. Kidney Int 2003, 63:143-155.
101. Hosoyamada M., Takiue Y., Morisaki H., et al. Establishment and analysis of SLC22A12 (URAT1) knockout mouse. Nucleosides Nucleotides Nucleic Acids 2010, 29:314-320.
102. Sharma S., Sundararajan A., Suryawanshi A., et al. T cell immunoglobulin and mucin protein-3 (Tim-3)/Galectin-9 interaction regulates influenza A virus-specific humoral and CD8 T-cell responses. Proc Natl Acad Sci U S A 2011, 108:19001-19006.
103. Assem M., Schuetz E.G., Leggas M., et al. Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem 2004, 279:22250-22257.
104. Van Aubel R.A., Smeets P.H., van den Heuvel J.J., Russel F.G. Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am J Physiol Renal Physiol 2005, 288:F327-F333.
105. Shimada H., Moewes B., Burckhardt G. Indirect coupling to Na+ of p-aminohippuric acid uptake into rat renal basolateral membrane vesicles. Am J Physiol 1987, 253(5 Pt 2):F795-F801.
106. Kaufhold M., Schulz K., Breljak D., et al. Differential interaction of dicarboxylates with human sodium-dicarboxylate cotransporter 3 and organic anion transporters 1 and 3. Am J Physiol Renal Physiol 2011, 301:F1026-F1034.